Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Novocure Ltd Stock Research

NVCR

17.78USD-0.40(-2.20%)Market Closed
Watchlist

Market Summary

USD17.78-0.40
Market Closed
-2.20%

NVCR Alerts

NVCR Stock Price

NVCR RSI Chart

NVCR Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-10.87

Price/Sales (Trailing)

3.73

EV/EBITDA

-13.96

Price/Free Cashflow

-41.29

NVCR Price/Sales (Trailing)

NVCR Profitability

Operating Margin

77.65%

EBT Margin

-24.96%

Return on Equity

-32.62%

Return on Assets

-12%

Free Cashflow Yield

-2.42%

NVCR Fundamentals

NVCR Revenue

Revenue (TTM)

507.7M

Revenue Y/Y

-10.52%

Revenue Q/Q

3.17%

NVCR Earnings

Earnings (TTM)

-174.4M

Earnings Y/Y

-139.16%

Earnings Q/Q

-8.21%

Price Action

52 Week Range

17.73120.03
(Low)(High)

Last 7 days

-10.8%

Last 30 days

-42.9%

Last 90 days

-59.9%

Trailing 12 Months

-78.4%

NVCR Financial Health

Current Ratio

7.32

NVCR Investor Care

Shares Dilution (1Y)

1.89%

Diluted EPS (TTM)

-1.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for NVCR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-01
Cordova Ashley
sold
-19,264
21.8172
-883
chief financial officer
2023-09-01
Shah Pritesh
sold
-5,956
21.8172
-273
chief growth officer
2023-09-01
GROENHUYSEN WILHELMUS CM
sold
-6,414
21.8172
-294
chief operating officer
2023-08-02
Cordova Ashley
sold
-34,607
30.2511
-1,144
chief financial officer
2023-06-30
Weinberg Uri
acquired
10,760
35.28
305
chief innovation officer
2023-06-30
Shah Pritesh
acquired
12,947
35.28
367
chief growth officer
2023-06-30
Burke William Patrick
acquired
12,595
35.28
357
chief human resources officer
2023-06-30
Ben Arye Barak
acquired
10,160
35.28
288
general counsel
2023-06-30
Cordova Ashley
acquired
12,947
35.28
367
chief financial officer
2023-06-30
GROENHUYSEN WILHELMUS CM
acquired
12,912
35.28
366
chief operating officer

1–10 of 50

Which funds bought or sold NVCR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-13
CGC Financial Services, LLC
new
-
1,245
1,245
-%
2023-09-12
Farther Finance Advisors, LLC
new
-
166
166
-%
2023-08-23
WOLVERINE TRADING, LLC
new
-
271,031
271,031
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.49
-3,174,040
6,527,870
0.01%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-1,766,000
3,934,000
0.04%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-4.56
-163,918
312,290
-%
2023-08-16
Nuveen Asset Management, LLC
reduced
-1.53
-5,809,210
12,315,800
-%
2023-08-16
Thomas J. Herzfeld Advisors, Inc.
sold off
-100
-1,323
-
-%
2023-08-16
Sunbelt Securities, Inc.
reduced
-36.17
-1,492
1,245
-%
2023-08-15
BENJAMIN F. EDWARDS & COMPANY, INC.
sold off
-100
-8,000
-
-%

1–10 of 42

Latest Funds Activity

Are funds buying NVCR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NVCR
No. of Funds

Schedule 13G FIlings of Novocure

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital international investors
7.8%
8,155,909
SC 13G/A
Feb 13, 2023
capital world investors
12.3%
12,899,395
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.10%
9,547,336
SC 13G/A
Jan 31, 2023
blackrock inc.
7.2%
7,605,425
SC 13G/A
Jan 23, 2023
baillie gifford & co
8.45%
8,863,842
SC 13G/A
Apr 11, 2022
fmr llc
-
0
SC 13G/A
Feb 11, 2022
capital world investors
12.3%
12,723,214
SC 13G/A
Feb 11, 2022
capital international investors
11.1%
11,531,075
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

Recent SEC filings of Novocure

View All Filings
Date Filed Form Type Document
Sep 05, 2023
4
Insider Trading
Sep 05, 2023
4
Insider Trading
Sep 05, 2023
4
Insider Trading
Sep 01, 2023
144
Notice of Insider Sale Intent
Aug 28, 2023
8-K
Current Report
Aug 04, 2023
4
Insider Trading
Jul 27, 2023
8-K
Current Report
Jul 27, 2023
10-Q
Quarterly Report
Jul 21, 2023
8-K
Current Report
Jul 06, 2023
4
Insider Trading

Peers (Alternatives to Novocure)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
109.7B
19.5B
4.61% 32.58%
40.5
5.64
10.36% 30.30%
102.6B
6.7B
1.85% 46.31%
71.98
15.39
11.75% -0.66%
78.2B
13.4B
7.30% 33.81%
85.79
5.84
8.69% 3.17%
71.3B
19.0B
-3.08% 10.26%
44.09
3.79
0.46% -5.24%
43.7B
5.7B
-5.74% -17.48%
31.48
7.73
5.64% -4.53%
MID-CAP
10.1B
937.8M
5.52% 36.72%
345.25
10.72
16.30% 250.21%
7.5B
616.6M
-7.14% -29.65%
30.68
12.13
69.52% 343.68%
5.3B
1.1B
-4.57% -12.56%
25.23
4.84
12.63% 50.85%
2.7B
452.1M
-16.85% -42.51%
-27.51
6.04
24.99% 24.09%
1.5B
790.3M
-18.06% -57.30%
-6.6
1.87
3.21% -1604.53%
SMALL-CAP
1.6B
421.8M
-8.54% 49.60%
-9.62
3.81
44.49% -2.43%
952.1M
780.7M
-7.00% -11.88%
-26.45
1.22
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
620.2M
162.9M
-26.12% -63.06%
-11.73
3.81
42.67% 12.82%

Novocure News

Best Stocks
NovoCure Limited (NASDAQ: NVCR) Receives Moderate Buy ....
Best Stocks,
2 days ago
InvestorsObserver
Yahoo Finance
The Motley Fool
Stockhouse Publishing
The Motley Fool
Why NovoCure Stock Is Crashing Today.
The Motley Fool,
24 days ago
Investor's Business Daily
InvestorPlace

Returns for NVCR

Cumulative Returns on NVCR

10.5%


7-Year Cumulative Returns

-18.2%


5-Year Cumulative Returns

-45.6%


3-Year Cumulative Returns

Risks for NVCR

What is the probability of a big loss on NVCR?

99.6%


Probability that Novocure stock will be more than 20% underwater in next one year

89.6%


Probability that Novocure stock will be more than 30% underwater in next one year.

53.5%


Probability that Novocure stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NVCR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Novocure was unfortunately bought at previous high price.

Drawdowns

Financials for Novocure

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-2.8%508522538543545538535546545527494450409380351322294269248232217
Gross Profit-5.0%385406423427429422420432433419388346311287263235212188168159149
Operating Expenses3.8%576555512497483467464441419385357328304285264245230215202189179
  S&GA Expenses7.3%20118717416315414413712912612111811310810397.0091.0086.0082.0078.0072.0070.00
  R&D Expenses-0.7%22222420620820419820118817315313211298.0087.0079.0070.0065.0057.0051.0046.0042.00
EBITDA100.0%--102-63.54-64.17-51.21-41.26-41.72-7.6015.0036.0036.0029.0021.0016.0013.00------
EBITDA Margin100.0%--0.20*-0.12*-0.12*-0.09*-0.08*-0.08*-0.01*0.03*0.07*0.07*0.06*0.05*0.04*0.04*------
Interest Expenses75.2%26.0015.008.00-3.84-3.84-1.610.000.002.005.009.0012.0014.0014.0014.0014.0014.0014.0013.0012.0012.00
Earnings Before Taxes-23.4%-160-130-81.85-74.86-61.98-51.86-52.07-17.684.0021.0018.008.00-2.05-6.15-8.82-18.06-27.00-36.90-45.94-42.01-42.44
EBT Margin100.0%--0.25*-0.15*-0.14*-0.11*-0.10*-0.10*-0.03*0.01*0.04*0.04*0.02*-0.01*-0.02*-0.03*------
Net Income-23.7%-174-140-92.53-81.69-68.24-58.87-58.35-26.98-4.5712.0020.0019.0012.009.00-7.23-27.12-40.74-54.98-63.56-58.87-58.68
Net Income Margin100.0%--0.27*-0.17*-0.15*-0.13*-0.11*-0.11*-0.05*-0.01*0.02*0.04*0.04*0.03*0.02*-0.02*------
Free Cashflow100.0%--4.619.0020.0024.0036.0059.0010611399.0084.0040.0024.0022.0016.00------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-1.3%1,1591,1741,1921,1741,1631,1501,1391,1201,0971,0681,052431529502479444406370340316310
  Current Assets-2.2%1,0651,0891,1121,1021,0951,0811,0741,0691,0461,015999383488462440407370336321297290
    Cash Equivalents-15.9%157187115244368192210691361326246235198183179210182154143125117
  Inventory4.1%33.0032.0029.0027.0030.0029.0024.0023.0027.0028.0027.0026.0026.0023.0024.0024.0025.0024.0023.0022.0020.00
  Net PPE12.9%41.0036.0033.0030.0027.0025.0023.0012.0012.0012.0011.0010.0011.0010.009.008.008.008.008.009.009.00
Liabilities0.2%743742750729721714729707700695575124261261262253247244228201198
  Current Liabilities0.9%15014915914113512814312511611011495.0085.0084.0086.0080.0074.0071.0065.0048.0045.00
    LT Debt, Non Current0.1%567566566565564563562561561560430-150149149149149149149149149
Shareholder's Equity-3.8%416432441445442436410413397372477307268242218190159126112115112
  Retained Earnings-6.9%-888-831-778-741-714-690-685-659-646-631-631-635-645-646-650-655-657-655-643-628-616
  Additional Paid-In Capital3.2%1,3071,2661,2221,1891,1581,1281,1001,0741,0451,0061,111946917893871848818784757744730
Shares Outstanding0.4%10710610510510510410410410310310210110110099.0098.0096.0095.0093.0093.0091.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-216.9%-20.7518.0031.0049.0051.0061.0083.0012212811599.0053.0037.0033.0027.0036.0027.0011.00-1.86-21.58-24.67
  Share Based Compensation5.7%12812110710099.0010195.0093.0087.0078.0076.0070.0064.0059.0052.0048.0045.0041.0040.0036.0034.00
Cashflow From Investing-421.4%-209-40.26-139-510-58.04-216-144-259-414-415-47294.00-55.36-53.79-51.67-6.70-5.53-4.62-5.49-5.65-6.40
Cashflow From Financing15.8%20.0018.0015.0016.0015.0021.0026.00593449444440-12234.0049.0062.0056.0044.0035.0069.0068.0066.00

NVCR Income Statement

2023-06-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended6 Months Ended12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Income Statement [Abstract]     
Net revenues$ 126,051$ 140,866$ 248,233$ 278,413$ 537,840
Cost of revenues34,01828,50363,63256,230114,867
Gross profit92,033112,363184,601222,183422,973
Operating costs and expenses:     
Research, development and clinical studies55,42757,075115,13199,309206,085
Sales and marketing58,48844,750109,65782,634173,658
General and administrative40,77831,66682,72262,174132,753
Total operating costs and expenses154,693133,491307,510244,117512,496
Operating income (loss)(62,660)(21,128)(122,909)(21,934)(89,523)
Financial income (expenses), net8,756(2,228)17,925(3,937)7,677
Income (loss) before income tax(53,904)(23,356)(104,984)(25,871)(81,846)
Income tax3,5146525,4952,78410,688
Net income (loss)$ (57,418)$ (24,008)$ (110,479)$ (28,655)$ (92,534)
Basic net income (loss) per ordinary share (in usd per share)$ (0.54)$ (0.23)$ (1.04)$ (0.27)$ (0.88)
Diluted net income (loss) per ordinary share (in usd per share)$ (0.54)$ (0.23)$ (1.04)$ (0.27)$ (0.88)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)106,289,073104,627,789105,979,791104,408,164104,660,476
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)106,289,073104,627,789105,979,791104,408,164104,660,476

NVCR Balance Sheet

2023-06-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 156,978$ 115,326
Short-term investments783,837854,099
Restricted cash516508
Trade receivables, net70,98886,261
Receivables and prepaid expenses20,14825,959
Inventories33,02329,376
Total current assets1,065,4901,111,529
LONG-TERM ASSETS:  
Property and equipment, net41,15632,678
Field equipment, net11,51912,684
Right-of-use assets26,27823,596
Other long-term assets14,57211,161
Total long-term assets93,52580,119
TOTAL ASSETS1,159,0151,191,648
CURRENT LIABILITIES:  
Trade payables82,53685,197
Other payables, lease liabilities and accrued expenses67,55173,580
Total current liabilities150,087158,777
LONG-TERM LIABILITIES:  
Long-term debt, net567,150565,509
Deferred revenues8072,878
Long-term leases20,32918,762
Employee benefit liabilities4,8404,404
Other long-term liabilities119148
Total long-term liabilities593,245591,701
TOTAL LIABILITIES743,332750,478
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:  
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 106,605,331 shares and 105,049,411 shares at June 30, 2023 (unaudited) and December 31, 2022, respectively00
Additional paid-in capital1,306,6031,222,063
Accumulated other comprehensive income (loss)(1,981)(2,433)
Retained earnings (accumulated deficit)(888,939)(778,460)
TOTAL SHAREHOLDERS' EQUITY415,683441,170
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$ 1,159,015$ 1,191,648
Asaf Danziger
1170
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.